Why the study?
Is the changing utilization of lipid-lowering, antihypertensive, and oral hypoglycemic drugs associated with trends in early all-cause mortality in men and women with type 2 diabetes?
Is the changing utilization of lipid-lowering, antihypertensive, and oral hypoglycemic drugs associated with trends in early all-cause mortality in men and women with type 2 diabetes?
Increased utilization of statins, renin-angiotensin system drugs, and metformin is associated with a significant decline in early all-cause mortality among patients newly diagnosed with type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Early mortality decline after new diabetes diagnosis was associated with greater statin, RAS drug, and metformin use; hypothesis-generating and requires confirmation in trials.
Charlton et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: